Equashield is a leading provider of closed system transfer devices (CSTDs) designed to protect healthcare professionals from exposure to hazardous drugs.

Equashield's mission is to provide advanced, automated, and innovative solutions to protect healthcare workers and facilities from the risks associated with hazardous drug exposure and contamination.

Equashield was founded in Israel in 2009 by Eric Shem-Tov and Marino Kriheli. The company is headquartered in Port Washington, New York.


Equashield's product suite includes its Closed System Transfer Device (CSTD), and its CSTD-enabled Automated Pharmacy Compounding System. Equashield's CSTD is clinically proven to protect healthcare professionals from hazardous drug exposure.


Equashield's products are sold across five continents, and the Company is a leading CSTD provider in the largest global market, the United States, supported by USP <800> regulation, which requires the use of CSTDs in the administration of hazardous drugs.


Equashield covers more routes of exposure than alternative systems and has passed the proposed 2015 alcohol vapor containment protocol from NIOSH. Used by thousands of hospitals and clinics worldwide, the system is CE marked and substantiated by the FDA for preventing microbial ingress for up to seven days.


Equashield has received a $300M private equity funding on Oct 06, 2022. The deal valued the company rat a $1.3B post-money.





  • Year founded: 2009
  • Funding Info: $300M over 1 Round (Funding Type: Private Equity)
  • Yearly Revenue: NA
  • Employee Size: 201-500
  • Business Valuation: Valued at $1.3B as of Oct 06, 2022
  • City/Town: Port Washington
  • State: New York
  • Country: United States
Related businesses